Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Notes Payables (2022 - 2025)

Mangoceuticals' Notes Payables history spans 3 years, with the latest figure at $100000.0 for Q3 2025.

  • On a quarterly basis, Notes Payables changed N/A to $100000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $100000.0, a N/A change, with the full-year FY2024 number at $150000.0, changed N/A from a year prior.
  • Notes Payables hit $100000.0 in Q3 2025 for Mangoceuticals, down from $500000.0 in the prior quarter.
  • Over the last five years, Notes Payables for MGRX hit a ceiling of $500000.0 in Q2 2025 and a floor of $78260.0 in Q4 2022.
  • Historically, Notes Payables has averaged $183152.0 across 3 years, with a median of $100000.0 in 2025.